ArticleBMC cancer2025
RAS mutations and colorectal cancer metabolism: a metabolomic analysis of tissue samples.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systems Biology and Structure-Based In Silico Evaluations of Quercetin-Psychobiotic Interactions for the Management of Depression.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is the third most common cancer globally, with incidence and mortality rates projected to rise significantly by 2040. RAS mutations are prevalent in CRC and associated with poor prognosis, yet their role in early-stage CRC remains debated. Metabolomics has revealed metabolic profile differences between CRC patients and healthy individuals, as well as between RAS-mutant and wild-type CRC patients, but the specific roles and mechanisms of metabolites in these groups require further investigation.
methodsThis study collected 49 CRC tissue samples, including 28 RAS-mutant and 21 wild-type samples. Liquid chromatography - mass spectrometry (LC-MS) was used for metabolite analysis, and multivariate statistical analysis, differential metabolite analysis, and pathway enrichment analysis were employed to compare the metabolic characteristics of the two groups.
resultsMultivariate statistical analysis showed relatively large within-group variation but marked differences between the RAS-mutant (M1) and wild-type (W1) groups. Differential metabolite analysis identified 70 upregulated and 134 downregulated metabolites in the M1 group. For example, omega-hydroxy myristic acid and 4 S-hydroxylauric acid were upregulated, while SCHEMBL1056153 and Immepip were downregulated. Correlation analysis revealed relationships between certain metabolites. Pathway enrichment analysis indicated that differentially expressed metabolites were mainly enriched in pathways such as Choline metabolism in cancer, Drug metabolism - cytochrome P450, and beta-Alanine metabolism at KEGG Level 3. Reactome enrichment analysis also revealed associations with specific pathways.
conclusionThis study reveals significant metabolic differences between RAS-mutant and wild-type CRC, identifying key differential metabolites and enriched pathways. These findings enhance the understanding of RAS-mutant CRC metabolism and provide candidate metabolites and pathways that warrant further validation as diagnostic or therapeutic targets. However, the study’s limitations, such as the relatively small sample size, should be considered, and further research is needed to explore the clinical applications and significance of these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.